ASCO 2012 Roundup
• Cyclacel Pharmaceuticals Inc., of Berkeley Heights, N.J., provided new data from a Phase I trial of two product candidates, sapacitabine, a nucleoside analogue, and seliciclib, a CDK inhibitor, as an orally administered sequential treatment regimen in heavily pretreated patients with advanced solid tumors.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter